Alemtuzumab — Drug Intelligence | 5 EU Trials

Filter these 5 trials by condition, phase, country and more.

5 Registered trials

2 Recruiting

3 Completed trials

4 Sponsors

13 Countries

Phase III

Phase II/III

Phase II

Phase I (FiH)

Phase III: 1 Phase II/III: 1 Phase II: 1 Phase I (FiH): 2

Oversight events:

5 temporary halts across 2 trials

Indications tested

5 total

A Phase 1/2a Study of UCART20x22 in B-Cell Non-Hodgkin Lymphoma [NatHaLi-01] Recruiting

2022-501607-27-00 Phase I (FiH) 3 countries Cellectis
No Evidence Of Disease Activity After Autologous Haematopoietic Stem Cell Transplantation In Aggressive Multiple Sclerosis Recruiting

2024-515470-26-00 Phase II 1 country Fondazione Italiana Sclerosi Multipla Ente Del Terzo Settore/et S
A Phase 1/2a Study of UCART22 in B-cell Acute Lymphoblastic Leukemia (BALLI-01) Ended

2022-502305-15-00 Phase I (FiH) 3 countries Cellectis
LCH-IV International Collaborative Treatment Protocol for Children and Adolescents with Langerhans Cell Histiocytosis Ended

2024-512676-36-00 Phase II/III 12 countries St. Anna Childrens Cancer Research Institute GmbH
RAM-MS Ended

2024-510630-40-00 Phase III 4 countries Helse Bergen HF

Showing 1–5 of 5 trials